NEW YORK (GenomeWeb) –Definiens and MolecularMD said today that they will partner to provide customized diagnostic solutions in oncology.

Definiens specializes in what it calls "tissue phenomics" for biomarker and companion diagnostics development and commercialization. MolecularMD develops custom molecular diagnostic products and supports clinical trial services for targeted cancer therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.